

WHAT IS CLAIMED IS:

Sub
a' 1 1. A composition comprising a live attenuated *Streptococcus equi*
2 and an immunostimulant, said immunostimulant having the property of stimulating
3 mucosal immunity.

c 1 2. The composition of claim 1, wherein said *Streptococcus equi* is
2 non-encapsulated.

c 1 3. The composition of claim 1, wherein said immunostimulant is
2 saponin, metabolizable oil, bacterial toxoid, bacterial adjuvant, interleukin, interferon,
3 carbopol, dextran derivative, dimethyldioctadecylammonium bromide or a mixture
4 thereof.

c 1 4. The composition of claim 1, wherein said immunostimulant is
2 saponin.

a 1 5. The composition of claim 1, wherein said *Streptococcus equi* is
2 strain 709-27_A (ATCC 53186)

Sub #2 1 6. The composition of claim 4, wherein said saponin is in the
2 amount of from about 1 to about 10 mg/ml of said composition.

1 7. The composition of claim 4, wherein said saponin is in the
2 amount of from about 3 to about 7 mg/ml of said composition.

1 8. The composition of claim 4, wherein said saponin is in the
2 amount of from about 4 to about 6 mg/ml of said composition.

a 1 9 The composition of claim 1, wherein said *Streptococcus equi* is
2 strain 709-27_A (ATCC 53186) and said immunostimulant is saponin.

090073. "01 598
865 TO "E0060

- 1 10. A dosage form for nasal administration comprising the
2 composition of claim 1.

- 1 *See E3* 11. The dosage form of claim 10, wherein said *Streptococcus equi* is
2 strain 709-27_A and said immunostimulant is saponin.
(ATCC 53186)

- 1 *See 32* 12. The dosage form of claim 11, wherein said *Streptococcus equi* is
2 present in a maximum dose of about 1×10^9 .

- 1 13. The dosage form of claim 11, wherein said *Streptococcus equi* is
2 present in a minimum dose of about 1.7×10^7 .

- 1 *See E4* 14. The dosage form of claim 11 wherein said *Streptococcus equi* is
2 in a lyophilized form and said saponin is in a diluent.

- 1 15. A method of stimulating an immune response to *Streptococcus*
2 *equi* comprising contacting cells of the nasopharyngeal mucosa of an equine with a
3 composition of claim 1.

- 1 *See E5* 16. The method of claim 15, wherein said *Streptococcus equi* is
2 strain 709-27_A and said immunomodulator is saponin.
(ATCC 53186)

- 1 17. A method for preventing at least one of the symptoms associated
2 with *Streptococcus equi* infection in equine comprising administering an effective
3 amount of the composition of claim 1 nasally or by mouth to said equine.

- 1 *See E6* 18. The method of claim 17, wherein said *Streptococcus equi* is
2 strain 709-27_A and said immunomodulator is saponin.
(ATCC 53186)

- 1 *See E6* 19. The method of claim 17, wherein said attenuated *Streptococcus*
2 *equi* is in the amount of from about 10^5 to about 10^{11} CFU.
(Colony forming Unit (CFU))

1 20. The method of claim 17, wherein said attenuated *Streptococcus*
 2 *equi* is in the amount of from about 10^6 to about 10^{10} ^{Colony Forming Unit (CFU)} _{CFU}.

1 21. The method of claim 17, wherein said attenuated *Streptococcus*
 2 *equi* is in the amount of from about 10^7 to about 10^9 ^{Colony Forming Unit (CFU)} _{CFU}.

add 17

09007385.011598